Within these 8 studies, 5 included HER2-positive breast cancer patients that received HER2-targeted therapy with or without chemotherapy (55–59), 1 study included TNBC patients who received combination of immunotherapy and chemotherapy (60), 1 study included hormone receptor positive breast cancer patients received chemotherapy combined with anti-angiogenesis therapy (5) and 1 study included non-specific patients received chemotherapy with or without HER2-trageted therapy (52) (Table 4). Here, ERBB2 is linked to breast carcinoma.